Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Summary

This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in two patient cohorts for up to 114 previously treated NSCLC patients with any systemic therapy (57 patients with EGFR exon 20 insertion mutations and 57 patients with HER2 exon 20 insertion mutations).

Timeline

Start

2019-07-30

Primary completion

2020-04-13

Completion

2020-04-13

Drugs

Indications